A 2012 Australian-based case-control study 20 suggests that concomitant sodium valproate administration (odds ratio: 2.59) and rapid dose escalation (odds ratio: 1.26) may be significant risk factors for CIM development.
← all excerpts
Clozapine-induced myocarditis in an adolescent male with DiGeorge Syndrome.
1
—
—